Kelly Felps, MD
Internal Medicine · Fort Worth, TXNPI 1205804366
Payments from drug & device makers
Across 73 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$232
- AbbVie$175
- GSK$104
- Pfizer$90
- Boehringer Ingelheim$78
- Biohaven Pharmaceutical Holding Company Ltd.$66
- plus $506 from 18 others
What the payments were for
- Food & beverage$1,252100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $232 |
| AbbVie | 10 | $175 |
| GSK | 6 | $104 |
| Pfizer | 6 | $90 |
| Boehringer Ingelheim | 4 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $66 |
| Cranial Technologies, Inc | 4 | $66 |
| Merck | 3 | $61 |
| Lilly USA, LLC | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| AstraZeneca | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Tonix Medicines, Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $13 |
How this compares
$1,252 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $72,629 |
| EliquisApixaban | 57 | $64,481 |
| JanuviaSitagliptin Phosphate | 24 | $28,074 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,709 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,976 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,064 |
| SynthroidLevothyroxine Sodium | 53 | $3,504 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,204 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,717 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,365 |
| Rosuvastatin Calcium | 197 | $2,167 |
| Tamsulosin Hcl | 116 | $2,105 |
| Novolog FlexpenInsulin Aspart | 11 | $1,983 |
| Atorvastatin Calcium | 199 | $1,952 |
| Metoprolol Succinate | 129 | $1,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $232 | $72,62957 claims |
| PfizerEliquis | $90 | $64,48157 claims |
| MerckJanuvia | $61 | $28,07424 claims |
| GSKTrelegy Ellipta | $104 | $20,70917 claims |
| AstraZenecaSymbicort | $28 | $4,06411 claims |
| AbbVieSynthroid | $175 | $3,50453 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Fort Worth
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.